biotech / news / / ThePrint
To restore hearing, Otarmeni delivers the OTOF gene into the inner ear through a surgical injection, using adeno-associated virus (AAV) therapy.
Otarmeni is the world's first approved gene therapy drug for hearing loss using double-AAV technology.
KEY POINTS
- Regeneron plans to offer Otarmeni free of cost in the US, marking a unique strategy.
- India lacks a nationwide newborn hearing screening program, with under 20% coverage versus 85-97% in Europe and the US.
- CMC Vellore conducted India's first successful human gene therapy trial for haemophilia A in 2024 with zero bleeding events.
- India's first CRISPR-based gene therapy for sickle cell disease, BIRSA-101, was launched in 2025 but awaits clinical trials.
COMPANIES
Summarized by Newsio from ThePrint. How we summarize →